Alejandro Jiménez-Sánchez

Alejandro Jiménez-Sánchez

Auto-generated profile, based on publicly available information

Alejandro Jiménez-Sánchez

Memorial Sloan Kettering Cancer Center 1 Computational and Systems Biology Program New York, New York

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AJAlejandro Jiménez-Sánchez
Alejandro Jiménez-Sánchez
PCPaulina Cybulska
Paulina Cybulska
KMKatherine LaVigne Mager
Katherine LaVigne Mager
SKSimon Koplev
Simon Koplev
OCOliver Cast
Oliver Cast
MMMartin L. Miller
Martin L. Miller

13 December 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
AJAlejandro Jiménez-Sánchez
Alejandro Jiménez-Sánchez
OCOliver Cast
Oliver Cast
MMMartin L. Miller
Martin L. Miller
Various computational approaches have been developed for estimating the relative abundance of different cell types in the tumor microenvironment (TME) using bulk tumor RNA data. However, a comprehensive comparison across diverse datasets that objectively evaluates the performance of these approaches has not been conducted. Here, we benchmarked seven widely used tools and gene sets and introduced ConsensusTME, a method that integrates gene sets from all the other methods for relative TME cell estimation of 18 cell types. We collected a comprehensive benchmark dataset consisting of pan-cancer data (DNA-derived purity, leukocyte methylation, and hematoxylin and eosin–derived lymphocyte counts) and cell-specific benchmark datasets (peripheral blood cells and tumor tissues). Although none of the methods outperformed others in every benchmark, ConsensusTME ranked top three in all cancer-related benchmarks and was the best performing tool overall. We provide a Web resource to interactively explore the benchmark results and an objective evaluation to help researchers select the most robust and accurate method to further investigate the role of the TME in cancer (www.consensusTME.org). Significance: This work shows an independent and comprehensive benchmarking of recently developed and widely used tumor microenvironment cell estimation methods based on bulk expression data and integrates the tools into a consensus approach.

25 March 2022 in Science Advances
Verified
Journal Article
Open access
TWThomas Walle
Thomas Walle
JKJoscha A. Kraske
Joscha A. Kraske
BLBoyu Liao
Boyu Liao
BLBénédicte Lenoir
Bénédicte Lenoir
CTCarmen Timke
Carmen Timke
PHPeter Huber
Peter Huber
Radiotherapy is a mainstay cancer therapy whose antitumor effects partially depend on T cell responses. However, the role of Natural Killer (NK) cells in radiotherapy remains unclear. Here, using a reverse translational approach, we show a central role of NK cells in the radiation-induced immune response involving a CXCL8/IL-8–dependent mechanism. In a randomized controlled pancreatic cancer trial, CXCL8 increased under radiotherapy, and NK cell positively correlated with prolonged overall survival. Accordingly, NK cells preferentially infiltrated irradiated pancreatic tumors and exhibited CD56 dim -like cytotoxic transcriptomic states. In experimental models, NF-κB and mTOR orchestrated radiation-induced CXCL8 secretion from tumor cells with senescence features causing directional migration of CD56 dim NK cells, thus linking senescence-associated CXCL8 release to innate immune surveillance of human tumors. Moreover, combined high-dose radiotherapy and adoptive NK cell transfer improved tumor control over monotherapies in xenografted mice, suggesting NK cells combined with radiotherapy as a rational cancer treatment strategy.

25 November 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JEJimmy Van den Eynden
Jimmy Van den Eynden
AJAlejandro Jiménez-Sánchez
Alejandro Jiménez-Sánchez
MMMartin L. Miller
Martin L. Miller
ELErik Larsson
Erik Larsson

17 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
HVHarini Veeraraghavan
Harini Veeraraghavan
HVHerbert Alberto Vargas
Herbert Alberto Vargas
AJAlejandro Jimenez-Sanchez
Alejandro Jimenez-Sanchez
MMMaura Miccò
Maura Miccò
EMEralda Mema
Eralda Mema
ESEvis Sala
Evis Sala
Purpose: Develop an integrated intra-site and inter-site radiomics-clinical-genomic marker of high grade serous ovarian cancer (HGSOC) outcomes and explore the biological basis of radiomics with respect to molecular signaling pathways and the tumor microenvironment (TME). Method: Seventy-five stage III-IV HGSOC patients from internal (N = 40) and external factors via the Cancer Imaging Archive (TCGA) (N = 35) with pre-operative contrast enhanced CT, attempted primary cytoreduction, at least two disease sites, and molecular analysis performed within TCGA were retrospectively analyzed. An intra-site and inter-site radiomics (cluDiss) measure was combined with clinical-genomic variables (iRCG) and compared against conventional (volume and number of sites) and average radiomics (N = 75) for prognosticating progression-free survival (PFS) and platinum resistance. Correlation with molecular signaling and TME derived using a single sample gene set enrichment that was measured. Results: The iRCG model had the best platinum resistance classification accuracy (AUROC of 0.78 [95% CI 0.77 to 0.80]). CluDiss was associated with PFS (HR 1.03 [95% CI: 1.01 to 1.05], p = 0.002), negatively correlated with Wnt signaling, and positively to immune TME. Conclusions: CluDiss and the iRCG prognosticated HGSOC outcomes better than conventional and average radiomic measures and could better stratify patient outcomes if validated on larger multi-center trials.

26 November 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
JEJimmy Van den Eynden
Jimmy Van den Eynden
AJAlejandro Jiménez-Sánchez
Alejandro Jiménez-Sánchez
MMMartin L. Miller
Martin L. Miller
ELErik Larsson
Erik Larsson
Somatic mutations in cancer can result in the presentation of mutated peptides on the cell surface, eliciting an immune response. Mutant peptides are presented via HLA molecules and are known as neoantigens. It has been suggested that selection acts against the underlying mutations, leading to neoantigen depletion. Knowing the extent of this specific form of immunoediting may provide fundamental insights into tumour-immune interactions during tumour evolution. Here, we quantified the extent of neoantigen depletion in a wide range of human cancers by studying somatic mutations in the HLA-binding annotated exome, i.e. genomic regions that can be translated into presented peptides. We initially observed reduced non-synonymous mutation rates in presented regions, suggestive of neoantigen depletion. However, when compared to the expected mutation rates from a trinucleotide-based mutational signature model, depletion signals were negligible. This is explained by correlative relationships between the likelihood of mutagenesis in different nucleotide sequences and predicted HLA affinities for corresponding peptides. Our results suggest that signals of immunogenic negative selection are weak or absent in cancer genomics data and that other mechanisms to escape immune responses early during tumour evolution might be more efficient.